ZYBERNO
Stock Report
Updated Aug 30, 2026

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT)

Healthcare • NASDAQ

$25.19

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
21.0/100
POOR BUSINESS
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) scores 21/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-31.8%)
Debt-to-Equity (Solvency Risk):POOR (1.00x)
Operating Margin (Operational Efficiency):CRITICAL (-12.2%)
Return on Capital (Capital Efficiency):CRITICAL (-49.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) stock report — Zyberno Score 21/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ADPT generated -$29.54M in Owner Earnings. Capital was deployed as follows: $2.50M invested in capital expenditures. Reinvestment rate: 46.4%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:25.19
Market Cap:$4.03B

Valuation Multiples (3)

P/B Ratio:26.73x
P/S Ratio:13.07x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$3.93B

Price Action & Momentum (3)

Momentum Percentile:90 / 100
% of 52-Week High:95.0%
B. Profitability Assessment

Return Metrics (5)

ROA:-11.9%
Reinvestment Rate:46.4%
Fundamental Growth Rate (g):-23.1%

Margin Analysis (3)

Operating Margin Ttm:-12.2%
Net Margin Ttm:-20.7%
Ebitda Margin:-6.2%

TTM Performance (3)

Gross Margin Ttm:75.6%
Operating Margin Ttm:-12.2%
Net Margin Ttm:-20.7%

Yield Metrics (2)

Earnings Yield:-$1.59
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-145.4%
Latest Earnings Filed:2026-08-04

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):16.8%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.79x
Quick Ratio:4.68x
Cash Ratio:1.94x

Leverage Analysis (3)

Debt To Equity Ttm:1.00x
Debt-to-Equity Ratio:1.00x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-4.96x
Times Interest Earned:-4.96

Capital Structure (4)

Working Capital:332,851,000.00
Cash And Cash Equivalents:169,873,000.00
Long Term Debt:$66.80M
Net Debt:-$94.25M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $308.08M
Linear Growth: 16.8%
📊 Click to view full ADPT Revenue analysis & methodology →
Cost Of Revenue Ttm:$75.25M

Profitability Breakdown (2)

Gross profit TTM: $232.83M
Linear Growth: 25.0%
📊 Click to view full ADPT Gross Profit analysis & methodology →
-$37.46M

Bottom Line Performance (3)

-$63.85M
Income Before Tax:-$59.46M
Ebitda Ttm:-19,250,000.00

Operating Expenses (5)

Operating Expenses:345,540,000.00
R And D Expense:88,208,000.00
Sga Expense:79,668,000.00
Income Tax Expense:$688.00K
Interest Expense:11,508,000.00

Expense Ratios (3)

R And D To Revenue Percentage:123.3%
Sga To Revenue Percentage:111.3%
Ebitda Margin:-6.2%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$640.68M
Current Assets:$420.56M
Ppe Net:29,451,000.00
Goodwill:118,972,000.00
Intangible Assets:$884.00K

Liability Structure (4)

Total Liabilities:490,016,000.00
Current Liabilities:87,712,000.00
Long Term Debt:$66.80M
Short Term Debt:$8.82M

Equity & Capital (3)

Equity:$150.66M
Retained Earnings:-$1.42B
Common Stock:340,000,000.00

Working Capital Items (3)

Accounts Receivable:49,513,000.00
Inventory:10,497,000.00
Accounts Payable:5,241,000.00

Special Items (2)

Contract Liabilities:53,863,000.00
Stock Based Compensation:11,119,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$27.04M-$29.54M

Investment Activities (2)

Investing Cash Flow:$9.14M
Capital Expenditures Ttm:2,496,000.00

Financing Activities (3)

Financing Cash Flow:$7.50M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:18,209,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.40
-$0.40
Earnings Per Share Ttm:-$0.40

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.93
Operating Cash Flow Per Share:-$0.29

Book Value & Capital (2)

Book Value Per Share:$0.94
Cash Per Share:1.06

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.57x
Working Capital Turnover Ttm:0.93x

Receivables Management (2)

Receivables Turnover Ttm:6.22x
Days Sales Outstanding Ttm:58.66

Inventory Management (2)

Inventory Turnover Ttm:7.17x
Days Inventory Outstanding Ttm:50.91

Payables & Cash Cycle (2)

Days Payable Outstanding:25.42
Cash Conversion Cycle:84.15
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:35.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$29.54M

Damodaran Growth Analysis (2)

Reinvestment Rate:46.4%
Fundamental Growth Rate (g):-23.1%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):16.8%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):25.0%
Book Value Growth Rate (Linear):-24.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:ADPT
Company Name:ADAPTIVE BIOTECHNOLOGIES CORPORATION
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:159.86M
Shares Outstanding Basic:159.86M
Shares Outstanding Diluted:159.86M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 22:49:19 UTC
Data Timestamp:2026-08-30T22:49:19.262532
Scroll to Top